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ABSTRACT 
Synchronized use of radiotherapy and chemotherapy has been the gold standard in the treatment of resectable as well as locally 
advanced head and neck cancer over the past few decades. Radiosensitizers play a key role in sensitizing the tumor cells to 
radiation, thereby surpassing the normal cells from radiation, thus protecting them. Among the many available radiosensitizers, 
taxanes being hydrophobic mitotic inhibitors, have indisputably proven effective in the treatment of many malignancies. This 
review focuses on taxane as a potential radiosensitizer in the treatment of head and neck squamous cell carcinomas.  
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ead and Neck Squamous cell carcinoma (HNSCC) 
is the fifth most common cancer worldwide, with a 
global annual incidence of approximately 500,000 
cases [1]. It is an aggressive epithelial malignancy with 
poor prognosis. As malignancy is linked to abusive habits, 
many patients present with notable comorbidities linked to 
lifestyle, a factor that limits the delivery of effective 
antitumor therapy. Along with the conventional treatment 
options, several novel therapeutic approaches for HNSCC 
have emerged over the past decade which include 
combinations of surgery, radiotherapy and chemotherapy.  
Concomitant chemoradiation is known to now provide 
better outcomes in terms of local control and survival in 
head and neck cancer [2].  
There are therapeutic agents which have the potential 
to sensitize tumor cells to the effects of radiation, thereby 
improving the therapeutic ratio, taxane is one such agent 
that is new in HNSCC. Taxane has a significant antitumor 
activity and are commonly used in treating both locally 
advanced and distantly metastatic disease. Of late these 
agents have been tested in the treatment of squamous cell 
carcinoma of the head and neck in combination with other 
chemotherapeutic agents, targeted drugs, and radiotherapy  
 
in in-vitro experiments and in the clinic as first-line 
treatment of patients with metastatic/recurrent and locally  
advanced HNSCC [3]. This review focuses on the role of 
taxanes as redaiosensitizer in the management of 
squamous cell carcinoma of the head and neck.  
 
PHARMACOLOGY OF TAXANES 
Taxanes are being used in the treatment of wide variety of 
malignancies. The 2 main forms of taxanes are Paclitaxel 
and Docetaxel. Paclitaxel, discovered in 1971 was one of 
the first taxane which was used as a chemotherapeutic 
agent. It is a semisynthetic derivative isolated from the 
Pacific Yew tree (Taxus brevifolia). It has nonlinear 
kinetics that causes cumulative concentration in the body, 
thus with changes in doses may lead to unpredictable 
toxicities. Docetaxel is isolated from needles of European 
yew tree (Taxus baccata), has linear kinetics over the 
doses. Because of productive effects and noncumulative 
toxicity, this is preferred over paclitaxel in weekly 
radiosensitization. Both are made of Tetracycline 17-
carbon skeleton, are poorly water soluble, thus require 
vehicles for IV drug delivery. They are  metabolized in the  
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liver P450 system (cyp2C8 enzyme is responsible for 
paclitaxel hydroxylation, cyp3A4 for docetaxel 
hydroxylation) and are cleared through biliary system 
[4,5]. 
MECHANISM OF ACTION 
Taxanes inhibit and suppress cell growth, differentiation 
and proliferation of cancer cells. They act by promoting 
tubulin polymerization and the formation of stable 
microtubules affecting the normal mitotic process and 
leading to cell death. Taxanes bind to β tubulin and 
stabilize the microtubules and thus induce the mitotic 
block causing radiosensitization.  At the molecular level, 
with the stabilization of microtubules, cell cycle proteins 
V12 p34 kinase and cyclin B1 accumulate with increase in 
the incubation time, inducing the mitotic block. Taxanes 
also causes the phosphorylation of Bcl- 2 leading to 
apoptosis. Activation of the caspase-3-dependent pathway 
leads to DNA fragmentation. All these lead to the G2/M 
block which is the main mechanism of paclitaxel 
cytotoxicity and radiosensitization [3,4].   
EFFICACY: 
Paclitaxel and Docetaxel have been used as a single agent 
or in combination with chemotherapy and radiotherapy in 
the management of locally advanced HNSCC as well as in 
the recurrent/ metastatic HNSCC. Taxanes have a longer 
half-life and therefore have a consistent radiosensitization 
toward the end of the week. The combination docetaxel 
and cisplatin results in response rates from 40 to 71%, 
whereas when used as a single agent is the response rate is 
20% to 40% [3,4].  
ADVERSE EFFECTS:  
Taxanes are poorly soluble in water, therefore solvents are 
used with taxanes for better absorption contributes to 
neurotoxicity as well as hypersensitivity reactions 
requiring pretreatment with antihistimines and 
corticosteroids to administer them safely [5]. Main side 
effects are hematologic toxicity, infectious and 
gastrointestinal complications (nausea, vomiting, and 
diarrhea), and renal toxicity, significant myelosuppression, 
grade 3 or 4 leucopenia, neutropenia, grade 3/4 mucositis, 
acute hypersensitivities and skin reactions, peripheral 
neuropathies, myalgias, and fatigue are seen at cumulative 
doses [2,3].  
NOVEL TAXANES:  
Recently oral taxanes have emerged as analogues of 
existing taxanes with a possible broad range of antitumor  
 
activity. When compared to the available taxanes, these 
oral forms have advantages like ease of administration, 
better efficacy and lesser toxicity. Novel taxane analogs 
have been developed that are poor substrates for P-
glycoprotein, and are orally bioavailable, eliminating the 
need for complicated drug vehicles and iv. drug delivery. 
The novel oral taxanes have the potential advantages over 
iv. paclitaxel and docetaxel of a better toxicity profile and 
increased efficacy. Due to the oral route, it is easier to give 
them in smaller and more frequent doses, which may allow 
for an increase in the overall dose given, while optimizing 
toxicity [5]. 
 
CONCLUSION  
The use of taxanes has increased in frequency in SCCHN 
in recent years begging the exploration of novel taxane 
based clinical regimens in concurrence with radiation 
therapy in locally advanced HNSCC. Having peaked the 
pinnacle of enhanced biologic effects, wider applicability, 
less chances of intrinsic resistance in comparison to other 
radiosensitizers makes taxanes a promising drug in the 
field of chemoradiation. However, phase III studies are 
needed to prove the superiority of these approaches 
compared to standard treatment.  
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